Skip to main content
SpringerLink
Log in

In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

In order to define the most effective administration schedule of the combination of paclitaxel and oxaliplatin, we investigated the in vitro interaction between these drugs in a panel of three human cancer cell lines (AZ-521 gastric adenocarcinoma cell line, HST-1 tongue squamous carcinoma cell line, and KSE-1 esophageal squamous carcinoma cell line).

Materials and methods

Cytotoxic activity was determined by the WST-1 assay. Different administration schedules of the two drugs were compared and evaluated for synergism, additivity, or antagonism with a quantitative method based on the median-effect principle of Chou and Talalay. Cell cycle perturbation and apoptosis were evaluated by flow cytometry.

Results

Simultaneous treatment of cells with paclitaxel and oxaliplatin showed greater than additive effects. Upon 24-h sequential exposure, the sequence of paclitaxel followed by oxaliplatin showed synergistic effects in AZ-521 and HST-1 cells, and greater than additive effects in KSE-1 cells, while the opposite sequence yielded marked antagonistic effects in all three cell lines. Flow cytometric analysis indicated that paclitaxel induced G2/M arrest with subsequent induction of apoptosis in the sub-G1 phase. Apoptosis was most prominent when paclitaxel preceded oxaliplatin, which produced apoptosis in the majority of treated cells (75%). By contrast, the reverse sequence yielded only 39% induction of apoptotic cells, the rate being not different from those induced by each drug singly.

Conclusions

Our findings suggest that the interaction of paclitaxel and oxaliplatin is highly schedule-dependent and that the sequential administration of paclitaxel followed by oxaliplatin should thus be incorporated into the design of a clinical trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Becouarn D, Ychou M, Ducreux M, et al (1998) Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients: Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16:2739–2744

    CAS  PubMed  Google Scholar 

  2. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55

    Article  Google Scholar 

  3. Chou TC, Motzer RJ, Tong V, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86:1517–1524

    Google Scholar 

  4. Christen RD, Jekunen AP, Jones JA, Thiebaut F, Shalinsky DR, Howell SB (1993) In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest 92:431–440

    Google Scholar 

  5. Donehower RC, Rowinsky EK, Grochow LB, Lomgnecker SM, Ettinger DS (1987) Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 71:1171–1177

    Google Scholar 

  6. Dunn T, Schmoll HJ, Grunwald V, Bokemeyer C, Casper J (1997) Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 15:109–114

    Google Scholar 

  7. Extra JM, Espie M, Calvo F, et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299–303

    CAS  PubMed  Google Scholar 

  8. Faivre S, Kalla S, Cvitkovic E, et al (1999) Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann Oncol 10:1125–1128

    Google Scholar 

  9. Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N (1995) Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 15:393–398

    Google Scholar 

  10. Garufi C, Nistico C, Brienza S, et al (2001) Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 12:179–182

    Google Scholar 

  11. Ishiyama M, Shiga M, Sasamoto K, Mizogichi M, He P (1993) A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull 41:1118

    Google Scholar 

  12. Jennerwein MM, Eastman A, Khokhar A (1989) Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexane platinum (II) complexes. Chem Biol Interact 70:39–49

    Google Scholar 

  13. Kano Y, Akutsu M, Tsunoda S, Suzuki K, Yazawa Y (1996) In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cancer Chemother Pharmacol 37:525–530

    Article  Google Scholar 

  14. Kouroussis C, Agelaki S, Mavroudis D, Kakolyris S, Androulakis N, Kalbakis K, Souglakos J, Mallas K, Bozionelou V, Pallis A, Adamtziki H, Georgoulias V (2003) A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res 23:785–791

    Google Scholar 

  15. Liebmann JE, Fisher J, Teague D, Cook JA (1994) Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6:25–31

    Google Scholar 

  16. Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter G, Schellens JH (1998) Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 41:307–316

    Article  Google Scholar 

  17. Matsuoka H, Sugimachi K, Ueo H, Kuwano H, Nakano S, Nakayama M (1987) Sex hormone response of a newly established squamous cell line derived from clinical esophageal carcinoma. Cancer Res 47:4134–4140

    Google Scholar 

  18. Milross CG, Peters LJ, Hunter NR, Mason KA, Milas L (1995) Sequence-dependent antitumor activity of paclitaxel (Taxol) and cisplatin in vivo. Int J Cancer 62:599–604

    Google Scholar 

  19. Monnet I, Brienza S, Hugret F, et al (1998) Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC): Association pour le Traitement des Tumeurs Intrathoraciques. Eur J Cancer 34:1124–1127

    Google Scholar 

  20. Nakano S, Nakayama M, Ichinose I, Mitsugi K, Nagafuchi S, Niho Y (1989) Characterization of a newly established, TA-4-producing squamous carcinoma cell line derived from metastatic tongue carcinoma. Int J Cancer 44:301–306

    Google Scholar 

  21. Page JD, Husain I, Sancar A, Chaney SG (1990) Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 29:1016–1024

    Google Scholar 

  22. Parker RJ, Lee KB, Dabholkar M, Bostick-Bruton F, Simmis M, Reed E (1993) Influence of Taxol: cisplatin sequencing on cisplatin-DNA adduct repair in human ovarian cancer cells. Proc Am Assoc Cancer Res 34:356

    Google Scholar 

  23. Piccart MJ, Green JA, Lacave AJ, et al (2000) Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 18:1193–1202

    Google Scholar 

  24. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C (1997) Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 8:876–885

    CAS  PubMed  Google Scholar 

  25. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel. Biochem Pharmacol 52:1855–1865

    Article  CAS  PubMed  Google Scholar 

  26. Rowinsky EK (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48:353–374

    Article  Google Scholar 

  27. Rowinsky EK, Citardi MJ, Noe DA, Donehower RC (1993) Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine. J Cancer Res Clin Oncol 119:727–733

    Google Scholar 

  28. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667

    CAS  PubMed  Google Scholar 

  29. Sorenson CM, Eastman A (1988) Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 48:4484–4488

    Google Scholar 

  30. Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schroder J, Seeber S (1995) Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A:92–97

    Google Scholar 

  31. Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F (1999) Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 5:1189–1196

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine and Department of Biosystemic Science of Medicine, Graduate School of Medicine, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan

    Risa Tanaka, Hiroshi Ariyama, Baoli Qin, Yasushi Takii, Eishi Baba, Kenji Mitsugi, Mine Harada & Shuji Nakano

Authors
  1. Risa Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Ariyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Baoli Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasushi Takii
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eishi Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenji Mitsugi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mine Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shuji Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuji Nakano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tanaka, R., Ariyama, H., Qin, B. et al. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 55, 595–601 (2005). https://doi.org/10.1007/s00280-004-0966-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0966-z

Keywords

Search

Navigation